Cargando…
Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia
Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892950/ https://www.ncbi.nlm.nih.gov/pubmed/33614484 http://dx.doi.org/10.3389/fonc.2020.597601 |
_version_ | 1783652959717949440 |
---|---|
author | Lou, Yinjun Ma, Yafang Jin, Jie Zhu, Honghu |
author_facet | Lou, Yinjun Ma, Yafang Jin, Jie Zhu, Honghu |
author_sort | Lou, Yinjun |
collection | PubMed |
description | Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future. |
format | Online Article Text |
id | pubmed-7892950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78929502021-02-20 Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia Lou, Yinjun Ma, Yafang Jin, Jie Zhu, Honghu Front Oncol Oncology Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future. Frontiers Media S.A. 2021-02-05 /pmc/articles/PMC7892950/ /pubmed/33614484 http://dx.doi.org/10.3389/fonc.2020.597601 Text en Copyright © 2021 Lou, Ma, Jin and Zhu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lou, Yinjun Ma, Yafang Jin, Jie Zhu, Honghu Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title_full | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title_fullStr | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title_full_unstemmed | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title_short | Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia |
title_sort | oral realgar-indigo naturalis formula plus retinoic acid for acute promyelocytic leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892950/ https://www.ncbi.nlm.nih.gov/pubmed/33614484 http://dx.doi.org/10.3389/fonc.2020.597601 |
work_keys_str_mv | AT louyinjun oralrealgarindigonaturalisformulaplusretinoicacidforacutepromyelocyticleukemia AT mayafang oralrealgarindigonaturalisformulaplusretinoicacidforacutepromyelocyticleukemia AT jinjie oralrealgarindigonaturalisformulaplusretinoicacidforacutepromyelocyticleukemia AT zhuhonghu oralrealgarindigonaturalisformulaplusretinoicacidforacutepromyelocyticleukemia |